Drugs / HPN-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04481594 | Sep 2020 → Jul 2021 | metabolic dysfunction-associated steatohepatitis | Hepanova Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPN-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04481594 ↗ |
| Route | Oral | “orally administered HPN-01” NCT04481594 ↗ |